The Trump administration will let a Biden-era program that subsidized Medicare prescription drug premiums expire at year's end, a move that could raise costs for roughly 25 million seniors just months before midterm elections.
The Centers for Medicare and Medicaid Services announced it will not renew the Medicare Part D premium subsidy program for 2027. CMS Administrator Mehmet Oz framed the decision as cutting off a taxpayer-funded handout to insurance companies, writing on social media that "the Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies. This is unacceptable."
The program launched in 2024 to cushion the effects of the 2022 Inflation Reduction Act, which restructured Medicare Part D by capping annual out-of-pocket drug spending at $2,000 and allowing Medicare to negotiate prices on certain high-cost medications. When CMS created the subsidies, the agency said they could last at least three years. They lasted two. A Government Accountability Office report pegged the total cost at $9.8 billion across 2025 and 2026.
Now the question is what seniors will pay without them, and whether the administration's own data backs up its reassurances.
In a follow-up post, Oz insisted the market no longer needs the subsidy. "We are stabilizing the market, so this bailout is no longer needed," he wrote. "Premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums."
A CMS spokesperson echoed that line, saying the agency's internal data shows plan bids have stabilized. Among the roughly one quarter of Medicare beneficiaries enrolled in plans the subsidy program covered, "over 85 percent of beneficiaries will have access to a Part D plan that is either lower cost or less than a $10 increase next year," the spokesperson said.
But the national average monthly bid amount for 2027 stands at $296.05, up from $239.27 the prior year. That is a jump of nearly 24 percent. CMS plans to release new monthly cost estimates for Part D coverage in mid- to late-September, which will give seniors a clearer picture of what they will actually owe.
Juliette Cubanski, vice president and director of the Medicare Policy program at KFF, told reporters the subsidy had a measurable effect on what people paid each month:
"In 2026, the average premium reduction because of the subsidy program was $16 a month, and that might not sound like a lot, but to put it in context, the average stand-alone drug plan premium this year is $36 a month. So, people might have had to pay nearly 50 percent more for drug coverage this year if the demonstration hadn't been in place."
In plain terms: without the subsidy, a $36 monthly premium could have been closer to $52. For seniors on fixed incomes already stretched by higher grocery bills and housing costs, that is real money.
The White House, when asked for comment, pointed reporters to Oz's social media posts. The CMS spokesperson added that the agency "remains focused on enacting policies to lower the cost of drugs and drug coverage, not directing billions of dollars in subsidies to insurance companies."
That framing, taxpayer money flowing to insurers, not to patients, carries some force. The $9.8 billion the program spent over two years went to insurance companies to offset their costs, not directly into beneficiaries' pockets. Oz called it a "bailout," and the administration argues the subsidies were always meant to be temporary.
The administration has pursued other avenues on drug prices. President Trump has promoted the TrumpRx platform and pushed "most-favored-nation" deals with drug companies as part of a broader effort to bring prescription costs down. That broader push is the context the administration wants voters to see, not a single subsidy program winding down on schedule.
The decision fits a pattern. The administration has shown a willingness to cut federal health-care spending it views as wasteful or mismanaged, including a recent freeze of more than $1 billion in Medicaid payments to California and Minnesota over fraud concerns.
Healthcare advocacy groups and Democratic leaders wasted no time attacking the move. Senate Minority Leader Chuck Schumer called it a deliberate choice, saying the administration is "actively raising prescription drug costs for 25 million seniors."
Leslie Dach, founder and chair of Protect Our Care, rejected the fiscal-responsibility argument outright:
"It'd be like, this costs $5 billion a year, you know, the war is costing us $100 billion, and so this is a choice they've made. It's not fiscal responsibility."
Dach called the decision "a purposeful thing." Whether voters agree will depend on what the September premium numbers look like, and whether the administration's $10-or-less promise holds up under scrutiny.
The timing adds a layer of political risk. The announcement lands roughly three months before midterm elections, a window in which cost-of-living concerns dominate voter surveys. Republicans in Congress already allowed ObamaCare subsidies to expire just months earlier. Stacking another subsidy cut on top gives Democrats a simple, kitchen-table message heading into November.
That political vulnerability is something Senate Democrats have already tried to exploit on entitlement issues, pressuring the administration on Social Security policy even as both parties avoid the program's deeper fiscal problems.
David Lipschutz, co-director of the Center for Medicare Advocacy, raised a different concern. He said the subsidy cut could push more seniors away from stand-alone Part D drug plans and toward Medicare Advantage, the privately managed alternative the administration has expressed support for.
"[The cut] has the impact of favoring enrollment in Medicare Advantage Plans, which some stakeholders are in favor of, and the administration has seemed to express support for."
Lipschutz added that Medicare Advantage, despite its popularity, "ends up costing the Medicare program more." If the subsidy cut steers enrollment toward a costlier model, the savings the administration claims could prove illusory.
He predicted the administration would frame the move as part of its broader waste-and-fraud campaign. "I think they will try to look at the savings that the government will have by not going through with this demo and claiming that that's savings to the Medicare program," Lipschutz said. "'Look at everything we're doing to root out waste, fraud and abuse, and here are some potential savings that we got.'"
That strategy mirrors the administration's approach to Medicaid, where officials have demanded fraud documentation from states as a condition of releasing frozen funds.
The Washington Examiner reported that the national base beneficiary premium for Medicare Part D will be $41.33 in 2027, with annual increases capped at 6 percent through 2029 under federal law. That cap applies to the base premium, but individual plan premiums can vary widely, and the subsidy's removal means the gap between the base and what seniors actually pay could widen.
Approximately 23 million people were enrolled in stand-alone Medicare Part D drug plans in 2025, per the GAO report. Supporting sources put the affected population closer to 25 million. Either way, the universe of voters who will feel this change is enormous.
Cubanski framed the stakes in household terms:
"At the end of the day, I think what matters to people is how much more or less they have at the end of the month after all their bills are paid. If their prescription drug plan premiums are going to be up for 2027, that just kind of puts more pressure on household budgets that are already being squeezed by higher gas prices and higher housing costs and higher food costs."
Congress has shown appetite for restructuring entitlement programs, Sen. Bill Cassidy recently staked his final months in office on a $1.5 trillion Social Security overhaul, but cutting a benefit that 25 million seniors already receive is a different kind of political bet.
The CMS spokesperson insisted the subsidies were "only supposed to be temporary." That may be true on paper. But temporary programs that put money back in voters' pockets have a way of becoming permanent, and ending them has a way of showing up on the ballot.
If the September numbers confirm that most seniors really do face only modest increases, the administration will have a solid answer. If they don't, the White House will own a premium hike it chose to deliver three months before voters head to the polls. In Washington, timing is policy, and this one lands right on the doorstep.